As this report goes to press, the COVID-19 pandemic has been troubling us for half a year since the COVID-19 virus embarked on its worldwide triumph. By July 26, 2020 more than 15.8 million have been infected and more than 640,016 perished. The IMF declares that global economy faces its worst downturn since the Great Depression. Worldwide, desperate attempts are in progress to control what has become an extremely disruptive eruption.
Clearly, you ask yourself several questions:
- How can I contribute to the coronavirus eradication battle?
- Does this pandemic present my firm new business prospects?
- Where do I get reliable information to assist my decisions?
This report was constructed to answer these questions!
Why trust this report?
- The team which created this report was led by ex-executives of the medical industry and bio-security experts
- The team has published since 2006, 36 Pandemic related market reports
- Team members managed since 1974 medical industry companies, sales & marketing, and R&D departments
- As the COVID-19 pandemic knowledge changes all the time, we update the report once a month
Bottom Line: While other COVID-19 market reports are written (at best) by MBAs, this report is published by seasoned professionals for industry executives.
This pandemic is a perfect storm. It has revealed key flaws in healthcare systems. COVID-19 is precisely the sort of pandemic which healthcare agencies were created for: the virus is highly infectious, traverses’ borders easily and threatens our life and economy. Its prevalence varies around the globe, with countries like the USA, Brazil, Italy, and France struck exceptionally hard. As we write this report the pandemic is intensifying with atrocious velocity. Strong, decisive action and investments in the COVID-19 mitigation products & services are therefore an imperative.
The COVID-19 pandemic has led to acute deficiencies of many essential products and services, from PPE and ventilators to surge ICUs and PCR & Serologic tests. Never before has leading healthcare communities been faced with the likelihood of having to ration or function without critical medical supplies and services on this magnitude. On the backdrop of the need for essential medical products and services, a new market has emerged, the COVID-19 Pandemic Mitigation Products Market.
According to the Coronavirus Pandemic Mitigation Products and Services Market – 2020-2024 report scenarios, the annual market* size is expected to reach up to $478 Billion (scenario B). The U.S. and Chinese markets will dominate the global one during the forecast period.
To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:
- Optimistic scenario – assumes (among other things) that mass vaccination will commence by July 2021
- Conservative scenario – assumes (among other things) that no mass vaccination will be available until 2024
This 924-page 4-volume market report is the first and most comprehensive review of the global COVID-19 Pandemic Mitigation Products & Services market available today. The objective of this report is to provide today’s strategic decision-makers with an expert 360-degree, time-sensitive, detailed view of this interconnected market.
(*) Market size is year and scenario dependent.
The Coronavirus Pandemic Mitigation Products & Services Market – 2020-2024 report presents a thorough market analysis of 54 products & services, 6 end user, 4 revenue source, 5 regional and 13 national markets. Furthermore, the report provides updated extensive data of 37 key vendors.
As countries start to re-open, and you do your best to recover your business, the report brings to your attention multi-billion business opportunities that may assist your struggle to retain business continuity and growth. This newly formed market is not limited to the healthcare supplier’s industry; many business opportunities are being created for industries from contact tracing technologies to blockchain, from AI, big-data & deep learning to nonwoven fabrics.
Why Buy this COVID-19 Market Report?
A. Questions answered in this report include:
- What is the COVID-19 Pandemic Mitigation Products & Services market size and what are the forecasted trends during 2020-2024?
- What are the most attractive business opportunities?
- What drives the customers to purchase solutions and services?
- What are the COVID-19 Mitigation technology & services trends?
- What is the 212 sub-markets size over the 2020-2024 period?
- What are the challenges to market penetration & growth?
B. The COVID-19 Pandemic Mitigation Products Market size data is analyzed via 5 independent key perspectives.
With a highly fragmented market we address the “money trail” – each dollar spent in the global COVID-19 Pandemic Mitigation market is analyzed and crosschecked via 5 orthogonal viewpoints:
- By 54 Products and Services:
- By 6 Vertical Market:
- By 13 National Markets:
- By 5 Regional Markets:
- By 4 Revenue Source Markets:
C. Detailed market analysis frameworks for each of the market sectors are provided, including:
D. The report provides an updated extensive data of the leading 37 companies (including companies’ profile, recent annual revenues, COVID-19 mitigation activities & products and contact information).
E. The report includes over 2300 links to the COVID-19 Pandemic Mitigation community information sources
F. The report mentions > 450 Vendors including the following:
3M Company, 3Scan, Abbott , AbCellera, Advenio Technosys, Agfa Healthcare, Agilent Technologies, AiCure, Aindra, Allscripts Healthcare Solutions, Amara Health Analytics , Amazon , analyticsMD, Apixio, Apple, Arterys Inc, Atlas Wearables, Atomwise, Avalon Nutrition VITL, Babylon Health, Bay Labs, Behold.ai, benevolent.ai, BIOBEATS, BlueDot, Bollé Safety, Bullard, Buoy Health, Care Angel Wearables QorQL, Careskore, Clinithink, Cloud Pharmaceuticals, CloudMedx, CureMetrix Mental health Ginger.io, Cyrcadia, Deep 6 AI, Deep Genomics, Dell Technologies Inc., Delta Plus Group, Desktop Genetics Virtual mate Ada Health, DreaMed Diabetes, Dupont, EaglEyeMed, Eli Lilly, Encon Safety Products, Enlitic, EnsoData, Entopsis, Envisagenics Research iCarbonX, ERB Industries Inc., Ergodyne, Essilor of America, Flashback Technologies, Flow Health, Ford, Freenome, Frequency Therapeutics Inc., Fujifilm Holdings Corporation, Gateway Safety Inc., GE Healthcare, General Electric, General Motors, General Vision, Gentex Corporation, Gibco, Gilead Sciences, Globavir Biosciences, Google, Healint, Health Fidelity, HealthNextGen, HexArmor, Hindsait, Honeywell Safety Products, IBM, Imagen Technologies, Imagia Cybernetics, Infermedica, Infervision, Inovio Pharmaceuticals, Inside DNA, InSilico Medicine, Intel Corporation, Intendu, Invitrogen, Ion Torrent, Ironwear, Johnson & Johnson (Janssen), Jvion, Kapa Biosystems, Keen Eye Technologies, Kimberly-Clark Professional, Koninklijke Philips NV, Lexmark International Inc., LifeGraph, Lucina Health, Lumiata, Lunit, Lytics, Magnea, Maxim Biotech, Maxwell MRI, McKesson Corporation, MCR Safety, Medal, Medalogix, Medasense, MedAware, Medtronic, MedWhat, MedyMatch , Merck, Metabiota, Micron Technology, Microsoft Corporation, Mindshare Medical, Moderna, Morpheo, Niramai Health Analytix, Novarad Corporation, NuMedii, Numerate, Nuritas Pharma Turbine, Nvidia Corporation, Oncora Medical, Ovuline, PeerWell, Pfizer, Philips, Philips Healthcare, PhysIQ., Precision Health Intelligence, Predible Health, Profility, Proscia, pulseData, Pyramex Safety, Qualaris Healthcare Solutions, Qualcomm Incorporated, Qualcomm Incorporated, Qure. Ai, Radians Inc., Recursion Pharmaceuticals, Regeneron Pharmaceuticals, Roam Analytics , Roche, RxPREDICT, Safety Optical Service, Samsung Electronics Co., Ltd, Sanofi, Saykara, Sellstrom Manufacturing Company (SureWerx), Sense.ly, Sensory Inc., Siemens, Sigma-Aldrich Corp., Skymind Inc., Thermo Fisher Scientific, Toshiba, Vir Biotechnology Inc., VisionAid Inc., WuXi Biologics, Xilinx Inc..
G. The report includes 5 appendices:
COVID-19 pandemic mitigation market research team
The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen identification, E-health, decontamination, and biosecurity, PACS, teleradiology, PPE, computerized tomography, ultrasound, electron microscopy, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.
As early as January 20, 2020 we recruited all our analysts to research the COVID-19 pandemic mitigation related products purchases. We interviewed hundreds of experts, participated in more than 95 conferences and webinars, reviewed more than 1,500 publications and interviewed executives of more than 65 pandemic related companies.
The team published by August 2020 a portfolio of 32 COVID-19 mitigation industry market reports.